Home > Result Summaries: Compounds > GSK1521498 Result Summaries: GSK1521498 GSKStudy ID Phase Title Summary (Download) 111314 phase 1 A First-Time-In-Human, Three-Part, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects (0 citation(s)) 111848 phase 1 An open-label, non-randomized [11C]carfentanil PET study in healthy male subjects to investigate brain mu-opioid receptor occupancy, pharmacokinetics, and pharmacodynamics of single oral doses of GSK1521498 and naltrexone. (1 citation(s)) 111849 phase 1 A randomised, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of 10 days of repeat dosing of GSK1521498 in overweight or obese but otherwise healthy subjects. (0 citation(s)) 111850 phase 2 A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour and Related Brain Function, in Obese Subjects with Over-Eating Behaviours. (2 citation(s)) 115256 phase 1 A Randomised, Double-Blind, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects (0 citation(s))
